Is ELOX or MDCX more profitable?

Eloxx Pharmaceuticals' return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Eloxx Pharmaceuticals N/A N/A N/A Medicus Pharma N/A -3,137.84% -263.24%

Is TLPH or MDCX more profitable?

Talphera's return on equity of -87.28% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Talphera N/A -87.28% -51.36% Medicus Pharma N/A -3,137.84% -263.24%

Does the media prefer TLPH or MDCX?

In the previous week, Talphera and Talphera both had 1 articles in the media. Medicus Pharma's average media sentiment score of 1.00 beat Talphera's score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talphera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medicus Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HRTX or MDCX?

In the previous week, Heron Therapeutics and Heron Therapeutics both had 1 articles in the media. Heron Therapeutics' average media sentiment score of 1.36 beat Medicus Pharma's score of 1.00 indicating that Heron Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heron Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medicus Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate INCR or MDCX?

Medicus Pharma has a consensus target price of $9.00, suggesting a potential upside of 5,178.59%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Medicus Pharma is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is INCR or MDCX more profitable?

InterCure's return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Medicus Pharma N/A -3,137.84% -263.24%

Is CLNN or MDCX more profitable?

Medicus Pharma has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Clene -20,063.96% N/A -137.04% Medicus Pharma N/A -3,137.84% -263.24%

Does the media prefer CLNN or MDCX?

In the previous week, Clene and Clene both had 1 articles in the media. Medicus Pharma's average media sentiment score of 1.00 beat Clene's score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medicus Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Medicus Pharma (MDCX) Competitors

$0.17 -0.09 (-34.40%)

As of 09/3/2026 04:00 PM Eastern

Compare

MDCX vs. ELOX, TLPH, HRTX, INCR, and CLNN

Should you buy Medicus Pharma stock or one of its competitors? Medicus Pharma's main competitors and comparable companies include Eloxx Pharmaceuticals (ELOX), Talphera (TLPH), Heron Therapeutics (HRTX), InterCure (INCR), and Clene (CLNN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Medicus Pharma compare to Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

In the previous week, Medicus Pharma had 1 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 1 mentions for Medicus Pharma and 0 mentions for Eloxx Pharmaceuticals. Medicus Pharma's average media sentiment score of 1.00 beat Eloxx Pharmaceuticals' score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Eloxx Pharmaceuticals	Neutral
Medicus Pharma	Positive

Eloxx Pharmaceuticals presently has a consensus target price of $41.50, indicating a potential upside of 192.46%. Medicus Pharma has a consensus target price of $9.00, indicating a potential upside of 5,178.59%. Given Medicus Pharma's higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Eloxx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Eloxx Pharmaceuticals' return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Medicus Pharma	N/A	-3,137.84%	-263.24%

Eloxx Pharmaceuticals has a beta of -1862.26, indicating that its share price is 186,326% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market.

Eloxx Pharmaceuticals has higher revenue and earnings than Medicus Pharma. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36M	9.01	-$5.99M	-$1.54	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Eloxx Pharmaceuticals beats Medicus Pharma on 9 of the 15 factors compared between the two stocks.

How does Medicus Pharma compare to Talphera?

Talphera (NASDAQ:TLPH) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

In the previous week, Talphera and Talphera both had 1 articles in the media. Medicus Pharma's average media sentiment score of 1.00 beat Talphera's score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Talphera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medicus Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Talphera's return on equity of -87.28% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-87.28%	-51.36%
Medicus Pharma	N/A	-3,137.84%	-263.24%

37.7% of Talphera shares are held by institutional investors. 3.5% of Talphera shares are held by insiders. Comparatively, 8.1% of Medicus Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Talphera has higher revenue and earnings than Medicus Pharma. Talphera is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	2,076.40	-$14.29M	-$0.27	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A

Talphera has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market.

Talphera currently has a consensus target price of $3.00, suggesting a potential upside of 150.00%. Medicus Pharma has a consensus target price of $9.00, suggesting a potential upside of 5,178.59%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Talphera beats Medicus Pharma on 7 of the 13 factors compared between the two stocks.

How does Medicus Pharma compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

In the previous week, Heron Therapeutics and Heron Therapeutics both had 1 articles in the media. Heron Therapeutics' average media sentiment score of 1.36 beat Medicus Pharma's score of 1.00 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heron Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medicus Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Heron Therapeutics currently has a consensus price target of $2.00, suggesting a potential upside of 506.06%. Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 5,178.59%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Medicus Pharma is more favorable than Heron Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Heron Therapeutics has higher revenue and earnings than Medicus Pharma. Heron Therapeutics is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.40	-$20.19M	-$0.19	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A

Medicus Pharma has a net margin of 0.00% compared to Heron Therapeutics' net margin of -22.52%. Heron Therapeutics' return on equity of -293.02% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-22.52%	-293.02%	-10.00%
Medicus Pharma	N/A	-3,137.84%	-263.24%

Heron Therapeutics has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

80.0% of Heron Therapeutics shares are held by institutional investors. 6.1% of Heron Therapeutics shares are held by company insiders. Comparatively, 8.1% of Medicus Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Heron Therapeutics beats Medicus Pharma on 8 of the 14 factors compared between the two stocks.

How does Medicus Pharma compare to InterCure?

InterCure (NASDAQ:INCR) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

8.3% of InterCure shares are held by institutional investors. 0.2% of InterCure shares are held by insiders. Comparatively, 8.1% of Medicus Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

InterCure's return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Medicus Pharma	N/A	-3,137.84%	-263.24%

InterCure has higher revenue and earnings than Medicus Pharma. Medicus Pharma is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.73	-$10.37M	$0.15	35.07
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A

InterCure has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

Medicus Pharma has a consensus target price of $9.00, suggesting a potential upside of 5,178.59%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Medicus Pharma is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Medicus Pharma had 1 more articles in the media than InterCure. MarketBeat recorded 1 mentions for Medicus Pharma and 0 mentions for InterCure. Medicus Pharma's average media sentiment score of 1.00 beat InterCure's score of -1.87 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Very Negative
Medicus Pharma	Positive

Summary

InterCure beats Medicus Pharma on 8 of the 14 factors compared between the two stocks.

How does Medicus Pharma compare to Clene?

Clene (NASDAQ:CLNN) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

23.3% of Clene shares are held by institutional investors. 28.3% of Clene shares are held by company insiders. Comparatively, 8.1% of Medicus Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Clene and Clene both had 1 articles in the media. Medicus Pharma's average media sentiment score of 1.00 beat Clene's score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medicus Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Clene has higher revenue and earnings than Medicus Pharma. Clene is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	256.36	-$26.17M	-$3.50	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A

Clene currently has a consensus price target of $33.25, suggesting a potential upside of 733.33%. Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 5,178.59%. Given Medicus Pharma's higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Clene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Clene has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market.

Medicus Pharma has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-20,063.96%	N/A	-137.04%
Medicus Pharma	N/A	-3,137.84%	-263.24%

Summary

Clene beats Medicus Pharma on 9 of the 14 factors compared between the two stocks.

Get Medicus Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDCX vs. The Competition

Export

Metric	Medicus Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.42M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-0.07	787.27	273.29	25.38
Price / Sales	N/A	753.79	613.45	92.55
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	-5.68	12.33	12.89	6.14
Net Income	-$35.46M	$2.82B	$3.47B	$349.01M
7 Day Performance	-33.84%	2.59%	0.60%	-0.27%
1 Month Performance	-43.91%	6.95%	5.73%	0.68%
1 Year Performance	-90.68%	9.45%	25.35%	14.84%

Medicus Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDCX Medicus Pharma	3.2103 of 5 stars	$0.17 -34.4%	$9.00 +5,178.6%	-91.4%	$16.42M	N/A	N/A	N/A	News Coverage Positive News Gap Down High Trading Volume
ELOX Eloxx Pharmaceuticals	2.3689 of 5 stars	$16.00 -13.7%	$41.50 +159.4%	N/A	$64.64M	$6.36M	N/A	N/A
TLPH Talphera	2.3103 of 5 stars	$1.23 -2.4%	$3.00 +143.9%	+120.6%	$63.85M	$30K	N/A	19
HRTX Heron Therapeutics	2.1853 of 5 stars	$0.33 +6.4%	$2.00 +502.2%	-75.2%	$63.05M	$154.90M	N/A	300	Positive News Gap Up
INCR InterCure	0.6387 of 5 stars	$5.68 -4.5%	N/A	-34.7%	$62.14M	$78.47M	189.33	350	Negative News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDCX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medicus Pharma (MDCX) Competitors

MDCX vs. ELOX, TLPH, HRTX, INCR, and CLNN

How does Medicus Pharma compare to Eloxx Pharmaceuticals?

Summary

How does Medicus Pharma compare to Talphera?

Summary

How does Medicus Pharma compare to Heron Therapeutics?

Summary

How does Medicus Pharma compare to InterCure?

Summary

How does Medicus Pharma compare to Clene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX vs. The Competition

Medicus Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medicus Pharma (MDCX) Competitors

MDCX vs. ELOX, TLPH, HRTX, INCR, and CLNN

How does Medicus Pharma compare to Eloxx Pharmaceuticals?

Does the media prefer ELOX or MDCX?

Do analysts recommend ELOX or MDCX?

Is ELOX or MDCX more profitable?

Which has more risk and volatility, ELOX or MDCX?

Which has higher valuation & earnings, ELOX or MDCX?

Do insiders and institutionals believe in ELOX or MDCX?

Summary

How does Medicus Pharma compare to Talphera?

Does the media prefer TLPH or MDCX?

Is TLPH or MDCX more profitable?

Do insiders & institutionals have more ownership in TLPH or MDCX?

Which has stronger valuation & earnings, TLPH or MDCX?

Which has more risk & volatility, TLPH or MDCX?

Do analysts recommend TLPH or MDCX?

Summary

How does Medicus Pharma compare to Heron Therapeutics?

Does the media prefer HRTX or MDCX?

Do analysts rate HRTX or MDCX?

Which has stronger valuation and earnings, HRTX or MDCX?

Is HRTX or MDCX more profitable?

Which has more risk & volatility, HRTX or MDCX?

Do insiders and institutionals have more ownership in HRTX or MDCX?

Summary

How does Medicus Pharma compare to InterCure?

Do institutionals & insiders have more ownership in INCR or MDCX?

Is INCR or MDCX more profitable?

Which has higher valuation & earnings, INCR or MDCX?

Which has more volatility & risk, INCR or MDCX?

Do analysts rate INCR or MDCX?

Does the media prefer INCR or MDCX?

Summary

How does Medicus Pharma compare to Clene?

Do institutionals and insiders have more ownership in CLNN or MDCX?

Does the media prefer CLNN or MDCX?

Which has preferable earnings and valuation, CLNN or MDCX?

Do analysts rate CLNN or MDCX?

Which has more volatility and risk, CLNN or MDCX?

Is CLNN or MDCX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX vs. The Competition

Medicus Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools